These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23377614)

  • 1. Company restores access to multiple sclerosis drug after pressure from neurologists.
    Laurance J
    BMJ; 2013 Feb; 346():f703. PubMed ID: 23377614
    [No Abstract]   [Full Text] [Related]  

  • 2. Monoclonal antibodies: magic bullets with a hefty price tag.
    Shaughnessy AF
    BMJ; 2012 Dec; 345():e8346. PubMed ID: 23236036
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer drug shows promise for multiple sclerosis.
    BMJ; 2012 Nov; 345():e7469. PubMed ID: 23129493
    [No Abstract]   [Full Text] [Related]  

  • 4. Alemtuzumab for multiple sclerosis.
    Lancet; 2012 Nov; 380(9856):1792. PubMed ID: 23122653
    [No Abstract]   [Full Text] [Related]  

  • 5. Product licences for alemtuzumab and multiple sclerosis.
    Coles AJ; Compston A;
    Lancet; 2014 Mar; 383(9920):867-8. PubMed ID: 24607095
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurologists appeal to health secretary over withdrawal of drug for MS patients.
    Laurance J
    BMJ; 2012 Nov; 345():e7449. PubMed ID: 23125160
    [No Abstract]   [Full Text] [Related]  

  • 7. [Alemtuzumab and teriflunomide approved].
    Fischer S
    Med Monatsschr Pharm; 2013 Oct; 36(10):393-4. PubMed ID: 24266250
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA reversal sends mixed message to multiple sclerosis community.
    Dolgin E
    Nat Rev Drug Discov; 2015 Jan; 14(1):3-4. PubMed ID: 25549578
    [No Abstract]   [Full Text] [Related]  

  • 9. Lessons for clinical trials from natalizumab in multiple sclerosis.
    Chaudhuri A
    BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multiple sclerosis: current therapies and future perspectives].
    Matsushita T
    Nihon Rinsho; 2011 Nov; 69(11):2077-86. PubMed ID: 22111333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA's rejection of alemtuzumab divides neurologists.
    Mullard A
    Lancet; 2014 Mar; 383(9920):859. PubMed ID: 24616917
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk stratification and patient counseling for natalizumab in multiple sclerosis.
    Fox RJ; Rudick RA
    Neurology; 2012 Feb; 78(6):436-7. PubMed ID: 22282644
    [No Abstract]   [Full Text] [Related]  

  • 13. Genentech's Ocrevus heralds new chapter in MS treatment.
    Sheridan C
    Nat Biotechnol; 2017 May; 35(5):393-394. PubMed ID: 28486459
    [No Abstract]   [Full Text] [Related]  

  • 14. Accidental natalizumab administration in pregnancy in multiple sclerosis.
    Bayas A; Penzien J; Hellwig K
    Acta Neurol Scand; 2012 Jul; 126(1):e5-6. PubMed ID: 22671932
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab and multiple sclerosis: is it safe?
    Bourdette D
    Neurology; 2014 Jul; 83(1):17-8. PubMed ID: 24920853
    [No Abstract]   [Full Text] [Related]  

  • 16. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 17. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

  • 18. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
    Torjesen I
    BMJ; 2012 Apr; 344():e2959. PubMed ID: 22532011
    [No Abstract]   [Full Text] [Related]  

  • 19. Unified understanding of MS course is required for drug development.
    Coetzee T; Thompson AJ
    Nat Rev Neurol; 2018 Apr; 14(4):191-192. PubMed ID: 29326425
    [No Abstract]   [Full Text] [Related]  

  • 20. Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis
    Chin P; Chan AC
    Biochemistry; 2018 Feb; 57(5):474-476. PubMed ID: 29172456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.